Table S1: Antibiotic susceptibility testing on strains carrying plasmids pMHMC-004 and pMHMC-012

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Name/Method** | **Class** | **Intermediate range\*** | **SBJ-9961** | **ATCC 25931** | **ATCC25931 + pMHMC-004** | **ATCC25931 + pMHMC-012** |
| **Kirby Bauer (mm)** |  |  |  |  |  |  |
| Amikacin | Aminoglycoside | 15-16 | 25 | 25 | 25 | 25 |
| Gentamycin | Aminoglycoside | 13-14 | 25 | 25 | 25 | 25 |
| Tobramycin | Aminoglycoside | 13-14 | 25 | 25 | 24 | 25 |
| Amoxicillin & Clavulanic acid | Beta-lactam combination agents | 14-17 | 20 | 31 | 22 | 25 |
| Piperacillin & Tazobactam | Beta-lactam combination agents | 18-20 | 30 | 35 | 34 | 35 |
| Ertapenem | Carbapenem | 16-18 | 35 | 45 | 40 | 37 |
| Imipenem | Carbapenem | 14-15 | 30 | 34 | 31 | 32 |
| Meropenem | Carbapenem | 14-15 | 32 | 33 | 35 | 35 |
| Cefepime | Cephalosporin | 15-17 | 40 | 36 | 40 | 38 |
| Cefotetan | Cephalosporin | 13-15 | 37 | 36 | 36 | 36 |
| Ceftazidime | Cephalosporin | 15-17 | 35 | 34 | 35 | 35 |
| Ceftriaxone | Cephalosporin | 14-20 | 38 | 38 | 37 | 36 |
| Cephalothin | Cephalosporin | 15-17 | 19 | 20 | 19 | 20 |
| Sulfamethoxazole/ Trimethoprim | Combination | 11-15 | 6‡ | 29 | 6‡ | 24 |
| Ciprofloxacin | Fluoroquinolone | 16-20 | 14‡ | 37 | 38 | 37 |
| Levofloxacin | Fluoroquinolone | 14-16 | 14† | 35 | 34 | 35 |
| Aztreonam | Monobactam |  | 38 | 37 | 36 | 36 |
| Ampicillin | Penicillin | 14-16 | 6‡ | 24 | 6‡ | 23 |
| Colistin | Polymyxin |  | 16 | 16 | 15 | 15 |
| Sulfamethoxazole | Sulfonamide | 13-16 | 6‡ | 26 | 6‡ | 6‡ |
| Minocycline | Tetracycline | 15-18 | 17† | 22 | 29 | 17† |
| Tetracycline | Tetracycline | 15-18 | 6‡ | 21 | 21 | 6‡ |
| **Etest (mg/l)** |  |  |  |  |  |  |
| Azithromycin | Macrolides | #### | >256‡ | 8 | >256‡ | 6 |
| **Microdilution (mg/l)** |  |  |  |  |  |  |
| Streptomycin | Aminoglycosides | #### | ≥128‡ | 4 | 8 | ≥128‡ |

\* Intermediate range for resistance phenotypes, determined by CLSI. † = Intermediate. ‡ = Resistant. These tests were done for comprehensive antimicrobial resistance testing, not all drugs listed should be considered for treatment of shigellosis.